｜Edited by the Content Team of Zhong Peptide BiochemicalMarch 202514DayNovartis's Class 1 radiopharmaceuticals, [177Lu]oxodotreotide injection and gallium [68Ga]oxodotreotide injection kit, have received tacit approval from the Center for Drug Evaluation of the National Medical Products Administration for their clinical trial applications. The trials are approved to investigate "newly diagnosed extensive-stage small cell lung cancer (ES-SCLC)" and "the use of positron emission tomography (PET) to determine the SSTR-positive expression status in patients for screening purposes."
Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a type of lung cancer that has spread to both lungs and/or other parts of the body, particularly diagnosed as extensive-stage when the cancer can no longer be controlled by local treatments alone, such as surgery. Small Cell Lung Cancer (SCLC) is a highly aggressive cancer with rapid growth and significant metastatic potential.
Novartis is committed to reimagining medicine to improve people's quality of life and extend human lifespan.We deliver high-value medicines that address the greatest disease burdens in society through our technological leadership in R&D and innovative accessibility initiatives.In the process of exploring new drugs, we have been innovating tirelessly, and our R&D investment has always been at the forefront of the global industry.Novartis has approximately 106,000 employees from over 140 countries and regions worldwide, and nearly 800 million patients globally benefit from Novartis products.
